SLC5A2 and chronic kidney disease: Treatment with SGLT2 inhibitors in type 2 DM patients has been found to slow the course of chronic kidney disease (CKD) and adverse renal events progression, as shown in five clinical trials namely EMPA-REG, CANVAS, DECLARE, CREDENCE, and DAPA-CKD [20].